Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Cerebellar DBS in SCA1 and SCA3 Study

NCT: NCT07752095 · NOT_YET_RECRUITING

NCT IDNCT07752095
StatusNOT_YET_RECRUITING
Start Date2026-10
Completion2030-06
SponsorGordon H. Baltuch (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to evaluate the safety and feasibility of deep brain stimulation (DBS) in the deep cerebellar nuclei (DCN) in patients with Spinocerebellar Ataxia (SCA) types 1 and 3. Primary Objective: The incidence and nature of treatment-related adverse events across the entire study, including serious treatment-related adverse events such as intracerebral hemorrhage, infection, and serious or unanticipated adverse device effects (SADEs and UADEs). Secondary/Exploratory Objectives: * Evaluation of the effect of Dentate Nucleus (DN) - Deep Brain Stimulation (DBS). Ataxia severity will be quantified using the Scale of Assessment and Rating of Ataxia (SARA), Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia), and kinematics. * To characterize electrophysiological activity across the cerebellothalamocorticomuscular (CTCM) network at rest and during motor behaviors. * To examine how DN-DBS modulates oscillatory activity and coupling across the CTCM circuit in relation to improvements in controlling ataxia.

Frequently Asked Questions

What is Cerebellar DBS in SCA1 and SCA3 Study?

Cerebellar DBS in SCA1 and SCA3 Study is a clinical trial registered under NCT07752095. Current status: NOT_YET_RECRUITING.

What is the status of NCT07752095?

The current status of NCT07752095 (Cerebellar DBS in SCA1 and SCA3 Study) is: NOT_YET_RECRUITING.

When did Cerebellar DBS in SCA1 and SCA3 Study start?

Cerebellar DBS in SCA1 and SCA3 Study started on 2026-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.